Industrial Policy & Trade Monitor· 2663 actions· ✨ 89 recent

The British Business Bank, the UK government's state-owned economic development bank, announced a GBP 50 million cornerstone commitment to Epidarex Capital's new life sciences fund on 20 January 2026. The fund, Epidarex Capital IV, LP, went on to announce a first close of USD 145 million on 27 January 2026, with the Bank joined by the Strathclyde Pension Fund, the Scottish National Investment Bank, and other family-office and corporate investors. This is the Bank's second cornerstone commitment to an Epidarex fund, following a GBP 50 million stake in Epidarex Capital III UK, LP in 2020.

The British Business Bank, the UK government's state-owned economic development bank, took a GBP 10.5 million (USD 13.9 million) equity stake in EpilepsyGTx, a UCL-spinout gene-therapy company, as part of a USD 33 million Series A financing round announced 10 December 2025. The round also included XGEN Venture and an unnamed global biopharmaceutical company; proceeds fund first-in-human Phase 1/2a trials of EpilepsyGTx's lead gene-therapy candidate EPY201 for focal refractory epilepsy.

The British Business Bank, the UK government's state-owned economic development bank, agreed a GBP 75 million (USD 100 million) cornerstone commitment to SV8 Biotech Fund LP, the new flagship multi-stage therapeutics fund managed by SV Health Investors, announced 8 December 2025. It is the Bank's single largest fund commitment to date, taking its cumulative life-sciences fund commitments above GBP 560 million across 15 funds, which the Bank says have collectively leveraged GBP 3.04 billion of private-sector capital.

The National Reconstruction Fund Corporation (NRFC), Australia's AUD 15 billion sovereign industrial-financing vehicle, took a AUD 54 million (~USD 35 million) equity stake in Synchron, a Melbourne-founded (now US-headquartered) brain-computer interface company, announced 7 November 2025. The investment forms part of Synchron's broader ~AUD 305-308 million (~USD 200 million) Series D raise alongside investors including Qatar Investment Authority, In-Q-Tel and Double Point Ventures, and is earmarked to fund final clinical trials and US FDA regulatory approval of Synchron's Stentrode device — a minimally-invasive BCI implanted via blood vessel without open brain surgery. NRFC frames the deal as commercialising Australian-origin technology and building sovereign medical-device manufacturing and clinical-trial capability.

The UK Department for Science, Innovation and Technology and the Office for Life Sciences launched the Life Sciences Transformational R&D Investment Fund (TRIF) Pilot, a GBP 50 million (approx. USD 67.4 million) capital grant scheme for large-scale R&D projects in the life sciences sector. Only projects with total costs of at least GBP 100 million qualify, with grants typically covering 10-20% of total project costs. The pilot runs on a rolling-application basis until 31 March 2028 or until funding is exhausted.

On 17 September 2025 the General Office of the Shanghai Municipal People's Government issued Hufubangui [2025] No. 8, a five-year (26 September 2025 - 25 September 2030) state-aid framework to accelerate frontier-technology innovation and cultivate "future industries" across six domains — future manufacturing, future information, future materials, future energy, future space and future health. Targeted technology areas include cell and gene therapy, brain-computer interfaces, biomanufacturing, embodied intelligence (humanoid robotics/AI hardware), fourth-generation semiconductors, silicon photonics, 6G, neuromorphic computing, quantum technology, controlled nuclear fusion and regenerative medicine. Support is disbursed as tiered direct subsidies rather than tax relief, with named ceilings up to CNY 30 million per proof-of-concept/R&D platform and CNY 20 million per high-quality incubator or first-product/batch innovation award.

The British Business Bank, the UK government's economic development bank, announced an GBP 8 million equity investment into NRG Therapeutics Ltd on 8 September 2025 as part of an oversubscribed GBP 50 million (USD 67 million) Series B financing round. NRG Therapeutics develops small-molecule mitochondrial permeability transition pore (mPTP) inhibitors for neurodegenerative diseases including ALS/MND and Parkinson's. The round was led by SV Health Investors' Dementia Discovery Fund, with participation from M Ventures, Novartis Venture Fund, Criteria Bio Ventures, and existing investors Omega Funds and Brandon Capital; a British Business Bank representative joined NRG's board.

On 29 August 2025 the Pinggu District (Beijing) Science, Technology and Economic Informatization Bureau issued "Several Measures to Promote the High-Quality Development of High-End Manufacturing in Pinggu District" (平谷区促进高端制造业高质量发展若干措施), published to the district government portal on 25 September 2025 with a two-year validity period. The scheme offers manufacturers registered and operating in Pinggu a stack of output-growth, R&D, smart-factory, green-transformation, pharma/medical- device, auto-parts-supply-chain, and synthetic-biology subsidies, with per-recipient caps ranging from RMB 200,000 up to RMB 10 million for qualifying pharmaceutical/medical-device innovators.

The National Reconstruction Fund Corporation (NRFC), Australia's AUD 15 billion sovereign industrial-financing vehicle, committed AUD 150 million to Brandon Capital's Brandon BioCatalyst 6 (BB6) fund, announced 24 July 2025. Brandon Capital — Australasia's largest life-sciences venture capital manager, with over AUD 1 billion under management — closed BB6 at AUD 439 million total, with the NRFC contribution the largest single commitment. The fund backs early- and late-stage Australian medical-science companies developing therapeutics, medical devices and vaccines, with roughly one-third earmarked for early-stage ventures and the remainder for late-stage clinical development and commercialisation. NRFC frames the deal as building sovereign medical-manufacturing and R&D capability and keeping Australian biotech IP and jobs onshore rather than migrating offshore for follow-on capital.

On 22 July 2025, BNDESPAR — the equity-investment arm of Brazil's national development bank BNDES — approved a BRL 114 million (approx. USD 20.5 million) minority equity subscription in Grupo Santa Clara, a Ribeirão Preto (São Paulo)-based producer of special fertilizers and bioinputs founded in 1997. The deal gives BNDESPAR a 19.9% stake, implying a company valuation near BRL 570 million, and is BNDESPAR's first direct variable-income (equity) operation since the bank reactivated its equity-participation strategy in June 2025 — a decade after its last direct stock investment. Proceeds are earmarked to expand Santa Clara's biofactory in Jaboticabal (SP) and fund the group's growth plan toward BRL 1 billion in revenue by 2030.

On 23 June 2025, BNDES president Aloizio Mercadante announced that BNDESPAR — the equity-investment arm of Brazil's national development bank — would resume direct variable-income (equity) investing after roughly a decade, committing up to BRL 10 billion (~USD 1.8bn) to companies and funds focused on ecological transition, decarbonization and innovation. The commitment splits into up to BRL 5 billion in direct equity investments (open to applicants through December 2025) and up to BRL 5 billion deployed via investment funds, funded from proceeds of BNDESPAR's sale of mature-company stakes and dividend receipts rather than new fiscal outlay. The bank framed the relaunch as strengthening Brazil's capital markets while directing state capital toward green-economy and innovation targets of all company sizes.

Slovakia's Office of the Deputy Prime Minister for the Recovery Plan and Knowledge Economy approved a EUR 160 million state-aid scheme ("Schéma štátnej pomoci na podporu znalostnej ekonomiky, výskumu, vývoja a inovácií") on 4 June 2025 to fund business-sector research, development and innovation projects, with emphasis on experimental development and industrial research. The office subsequently opened two calls under the scheme, in biotechnology and in robotics/automation, on 16 June 2025 (deadline 16 August 2025); demand of 338 project proposals worth over EUR 800 million led the office to raise the allocation for those two calls from EUR 180 million to roughly EUR 230 million. Supported projects run through 2027.

The National Reconstruction Fund Corporation (NRFC), Australia's AUD 15 billion sovereign industrial-financing vehicle, took a AUD 27 million equity stake in PolyActiva, a Melbourne biotech developing a biodegradable ocular implant (Prezia/PA5108) that delivers glaucoma medication over 6-12 months as an alternative to daily eye drops. The investment, announced 30 May 2025, forms the majority of PolyActiva's AUD 40 million Series C round, with the remaining AUD 13 million from existing investor Brandon Capital. Funds will consolidate the company's R&D, analytics and manufacturing into a single Melbourne facility, grow its ~25-person workforce, and fund completion of a Phase 2b clinical trial, with commercialisation targeted for 2029.

The UK Department for Science, Innovation and Technology signed a grant agreement with BioNTech UK Ltd. providing up to GBP 129 million in government support over 10 years, underpinning BioNTech's planned GBP 1 billion (USD 1.3 billion) investment in UK research and development over the same period. The funding backs two new R&D hubs: a life-sciences research centre in Cambridge (genomics, oncology, structural biology, regenerative medicine) and an AI hub co-located with BioNTech's planned UK headquarters in London, run by its InstaDeep subsidiary. The government frames the deal as one of the largest single-company investments in UK life-sciences history and part of the Oxford-Cambridge Growth Corridor and Plan for Change industrial strategy.